A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 792 participants.
Also called NCT04560998
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 792 participants
- Sponsor
- Registry
-
NCT04560998 -
2019-003399-38
-
- Other papers using this trial's data
- Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Belgium, Canada, China, Czechia, Denmark, Germany, Greece, Hungary, India, Japan, Latvia, Malaysia, Norway, Poland, Russia, Spain, Sweden, Taiwan, Thailand
- Registry status
- Completed
Technical summary
Registry record NCT04560998. Randomized; quadruple masking; primary purpose treatment. Start 2020-10-01 (actual); primary completion 2024-06-05 (actual). Results posted on 2025-07-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
- Acronym
- STRIDE
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Peripheral Arterial Disease
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo (semaglutide)
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct04560998- Content hash
2b8ed9cc34122db73e81e1640a53aea62d87bda8b30646e251ebc7e318040424